Literature DB >> 10475238

Expression and characterization of anti-NCA-95 scFv (CEA 79 scFv) in a prokaryotic expression vector modified to contain a Sfi I and Not I site.

K Yi1, J Chung, H Kim, I Kim, H Jung, J Kim, I Choi, P Suh, H Chung.   

Abstract

The CEA 79 antibody has been used in bone marrow scintigraphy for the differential diagnosis of skeletal tumors and the evaluation of the bone marrow status of patients with various hematological disorders. The specific localization of radio-labeled CEA 79 antibody in bone marrow depends on its reactivity with NCA-95 (nonspecific cross-reacting antigen-95) present on the surface and in the cytosol of human granulocytes and myelopoietic cells. To make a CEA 79 scFv molecule that would be less immunogenic and more penetrating than the intact mouse immunoglobulin, we constructed a pRSET Sfi I/Not I expression vector. The scFv gene was then excised from a pCANTAB 5 E phage display vector by digestion with Sfi I and Not I and inserted into the pRSET Sfi I/Not I expression vector. Upon transformation of a BL21(DE3)pLysS strain of E. coli, CEA 79 scFv became expressed in inclusion bodies requiring a renaturation process for solubilization. The final yield of CEA 79 scFv was 5 mg per a liter of culture. The refolded CEA 79 scFv exhibited an affinity (Kd = 2.1 x 10(-9) M) equivalent to that of the original CEA 79 antibody (K(d) = 3.3 x 10(-9) M) and the same immunoreactivity to CEA and NCA-95 in Western blots and in immunohistochemical staining experiments.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10475238     DOI: 10.1089/027245799315899

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  4 in total

1.  Preparation of single chain variable fragment of MG(7) mAb by phage display technology.

Authors:  Z C Yu; J Ding; Y Z Nie; D M Fan; X Y Zhang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Expression and bioactivity identification of soluble MG7 scFv.

Authors:  Zhao-Cai Yu; Jie Ding; Bo-Rong Pan; Dai-Ming Fan; Xue-Yong Zhang
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

3.  Anti-idiotypic antibody as a potential candidate vaccine for Neisseria meningitidis serogroup B.

Authors:  In Ho Park; Ju Ho Youn; In-Hong Choi; Moon H Nahm; Se Jong Kim; Jeon-Soo Shin
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  Production and characterisation of a recombinant scFv reactive with human gastrointestinal carcinomas.

Authors:  D-J Kim; J-H Chung; Y-S Ryu; J-H Rhim; C-W Kim; Y Suh; H-K Chung
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.